Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lurbinectedin on QTc Interval in Solid Tumors
NCT02451007Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of lurbinectedin in solid tumor, sponsored by PharmaMar. Started Aug 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02451007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451007.